Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31257650 | 0.85 | AAK1 (0.39) | PRKCIEGFRAAK1MAPTKDM4E | |
| SCHEMBL931406 | 0.82 | HDAC1 (0.45) | PRKCIEGFRAAK1MAPTKDM4E | |
| SCHEMBL29569681 | 0.82 | HDAC1 (0.45) | PRKCIEGFRAAK1MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL15158292 | 0.80 | HDAC1 (0.44) | PRKCIEGFRAAK1MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL16277747 | 0.80 | HDAC1 (0.44) | PRKCIEGFRAAK1MAPTKDM4E | |
| SCHEMBL12190764 | 0.78 | APP (0.37) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL2018111 | 0.77 | ALDH1A1 (0.54) | EGFRAAK1MAPTKDM4EALDH1A1 | |
| SCHEMBL9102892 | 0.77 | AAK1 (0.43) | EGFRAAK1MAPTKDM4EALDH1A1 | |
| SCHEMBL29673248 | 0.77 | AAK1 (0.43) | EGFRAAK1MAPTKDM4EALDH1A1 | |
| SCHEMBL1957518 | 0.77 | AAK1 (0.39) | EGFRAAK1MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719605-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GlaxoSmithKline Intellectual Property (No.4) Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-3976604-B1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2026-01-21 | — | — | EP | disclosed |
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) | 2026-01-15 | — | — | US | disclosed |
| US-12492188-B2 | 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250339494-A1 | COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS | UNIV PARIS CITE (FR) | 2025-11-06 | — | — | US | disclosed |
| US-20250340539-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2025-11-06 | — | — | US | disclosed |
| US-20250333399-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KHORA SPV 1 LLC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12331039-B2 | Inhibitors of fibroblast growth factor receptor kinases | KHORA SPV 1, LLC (US) | 2025-06-17 | — | — | US | disclosed |
| CN-116157398-B | Oxadiazole-based selective histone deacetylase 6 inhibitors | 意大发马克股份公司 | 2025-03-11 | — | — | CN | disclosed |
| EP-4511022-A1 | COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS | Université Paris Cité (FR) | 2025-02-26 | — | — | EP | disclosed |
| US-7196102-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20050143426-A1 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. | 2005-06-30 | — | — | US | disclosed |
| US-6908935-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2005-06-21 | — | — | US | disclosed |
| EP-1509497-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | Amgen Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| CN-1186328-C | Substd. 5-benzyl-2,4-diaminopyrimidines | BASLIDE PHARMA AG (CH) | 2005-01-26 | — | — | CN | disclosed |
| US-20040082625-A1 | Calcium receptor modulating agents | AMGEN INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2003099776-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| US-6200976-B1 | FOR TREATING THROMBOSIS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-03-13 | — | — | US | disclosed |
| EP-1071669-A1 | BICYCLIC COMPOUNDS HAVING AN ANTI-THROMBITIC EFFECT | Boehringer Ingelheim Pharma KG (DE) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999054313-A1 | BICYCLIC COMPOUNDS HAVING AN ANTI-THROMBITIC EFFECT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082625-A1 | Calcium receptor modulating agents | PTH1R, CASR, CALCR | PRKCI 390/4885EGFR 619/4885AAK1 1085/4885 |
| US-20250339494-A1 | COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS | IL2, CXCL10, IFNG | PRKCI 668/4885EGFR 3587/4885AAK1 1873/4885 |
| US-12331039-B2 | Inhibitors of fibroblast growth factor receptor kinases | FGFR1, FGFR2, FGFR3 | PRKCI 272/4885EGFR 8/4885AAK1 471/4885 |
| US-12492188-B2 | 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis | TLR9, TLR1, TLR7 | PRKCI 682/4885EGFR 719/4885AAK1 1708/4885 |
| US-20250333399-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | PRKCI 272/4885EGFR 8/4885AAK1 471/4885 |
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | WRN, MSH2, MSH6 | PRKCI 1002/4885EGFR 4351/4885AAK1 3123/4885 |
| US-20050143426-A1 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | PTH1R, PTMS, SOST | PRKCI 382/4885EGFR 1698/4885AAK1 2201/4885 |
| US-20250340539-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 | CLK1, CLK2, CLK3 | PRKCI 464/4885EGFR 3136/4885AAK1 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.